Ropes & Gray advised EQRx in a strategic collaboration with Insilico Medicine to jointly advance artificial intelligence-driven drug discovery, development and commercialization of multiple disease targets. The deal was announced on March 24.
Under the agreement, the parties will identify and select up to three therapeutics targets leveraging Insilico's AI-driven platform. Insilico will lead drug discovery from small molecule identification through preclinical candidate nomination to IND-filing. EQRx will assume responsibility for driving clinical development, regulatory activities and commercialization.
The Ropes & Gray team was led by life sciences partner Abigail Gregor.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.